Special issue

European Archives of Psychiatry and Clinical Neuroscience

, Volume 251, Issue 4, pp 179-184

First online:

Erythropoietin – a novel concept for neuroprotection

  • Anna-Leena SirénAffiliated withMax-Planck-Institute for Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany, Tel.: +49-5 51/3 89 96 27, Fax: +49-5 51/3 89 59 70, E-Mail: siren@em.mpg.de
  • , Hannelore EhrenreichAffiliated withMax-Planck-Institute for Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany, Tel.: +49-5 51/3 89 96 27, Fax: +49-5 51/3 89 59 70, E-Mail: siren@em.mpg.de

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Neuroprotection as a means to prevent or oppose pathological neuronal loss in central nervous system disease of various pathophysiological origins represents a novel therapeutic approach. This approach is supported by extensive experimental evidence on cell culture and animal studies demonstrating beneficial effects of growth factors on neuronal survival and functional recovery. The clinical use of neuroprotective agents has been hampered by the toxicity of many of the compounds that showed promising therapeutic potential in animal studies. The focus of this review is on a novel neuroprotective approach with erythropoietin, a hematopoietic growth factor that: 1) is expressed in the human central nervous system, 2) is hypoxia-inducible, 3) has demonstrated remarkable neuroprotective potential in cell culture and animal models of disease, 4) has multiple protective effects (antiapoptotic, neurotrophic, antioxidant, angiogenic), and 5) is a clinically extremely well tolerated compound.

Key words Erythropoietin Neuroprotection Growth factor receptor Brain Human stroke